Immune tolerance in the liver fosters an immunosuppressive tumor microenvironment (TME) with increased infiltration of regulatory T cells and decreased content of effector CD8+ T cells, which leads to immune evasion of tumor cells.4,9 The relatively high interstitial fluid pressure in liver metastases caused by tumor-induced angiogenesis can also impede the delivery of drugs and diminish their antitumor activities.10 Therefore, novel drug combinations and treatment paradigms that target these critical malignant phenotypes of liver metastasis are worthy of assessment in GI cancers. The gene discussed is CD8A; the disease is neoplasm.